Roswell Park Comprehensive Cancer Center has formed an academic cooperation with the Jagiellonian University in Kraków.
The collaboration will see the two centers exchanging staff, students and scientific resources to undertake basic, translational and clinical research in order to advance the development of cancer therapies.
The agreement grew out of a July 2018 visit by Polish Secretary of State Anna Maria Anders to Roswell Park. Four Roswell Park faculty leaders, joined by Anders, recently traveled to Kraków to initiate the collaboration: Kunle Odunsi, deputy director, chair of gynecologic oncology and executive director of the Center for Immunotherapy; Pawel Kalinski, vice chair for translational research and Rustum Family Professor for Molecular Therapeutics and Translational Research; Agnieszka Witkiewicz, director of the Center for Personalized Medicine and chief for research in the Department of Pathology; and Danuta Kozbor, associate professor of immunology and microbiology.
The agreement is effective immediately, and could see exchange of students and faculty between the two centers as early as spring 2019.
Roswell Park partners with Jagiellonian University in Kraków
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
Table of Contents
YOU MAY BE INTERESTED IN
A year like 2025 has demanded a lot from all of us, between the Trump administration’s flooding of the zone, the impact of DOGE and MAHA initiatives on the National Cancer Program, and the personal toll of living amidst uncertainty. In many ways, 2025 was a test. Did the field of oncology pass? Did The Cancer Letter?


As trust in scientific and regulatory institutions frays and the meaning of “gold standard science” is increasingly contested, cancer research faces a credibility test of its own.


Earlier this month, NCI released a new Cancer Center Support Grant Notice of Funding Opportunity. Except for the elimination of the Plan to Enhance Diversity component and lengthening of the Shared Resource write-ups from three to six pages, the guidelines are essentially unchanged.


New Year’s Eve approaches, and with it, a chance to turn a new leaf with renewed energy, to reflect on—or perhaps, in the case of 2025, bemoan—the events of the year, and, most importantly, to celebrate.


2025 has, indisputably, been a year of change in oncology as the field grapples with shifting policy directions, RIFs, and uncertainty stemming from the Trump administration’s MAHA mission.





